{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Renal+Cell+Carcinoma&page=2",
    "query": {
      "condition": "Locally Advanced Renal Cell Carcinoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Renal+Cell+Carcinoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:51:18.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00024388",
      "title": "Chemotherapy in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "DHA-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theradex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-07-24",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Lexington, Kentucky + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00024388"
    },
    {
      "nct_id": "NCT04953104",
      "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Recurrent Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage IIIB Bladder Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Unresectable Bladder Urothelial Carcinoma",
        "Unresectable Renal Pelvis Urothelial Carcinoma",
        "Unresectable Ureter Urothelial Carcinoma",
        "Unresectable Urethral Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Diagnostic Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04953104"
    },
    {
      "nct_id": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IVA Gastric Cancer AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastric Cancer AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Endometrial Carcinoma",
        "Locally Advanced Gastric Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Head and Neck Squamous Cell Carcinoma",
        "Locally Advanced Hepatocellular Carcinoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Melanoma",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Renal Cell Carcinoma",
        "Locally Advanced Skin Squamous Cell Carcinoma",
        "Locally Advanced Triple-Negative Breast Carcinoma",
        "Locally Advanced Unresectable Breast Carcinoma",
        "Locally Advanced Unresectable Cervical Carcinoma",
        "Locally Advanced Unresectable Gastric Adenocarcinoma",
        "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Unresectable Renal Cell Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IIIA Cervical Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIB Cervical Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Lung Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma",
        "Unresectable Cervical Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Lung Non-Small Cell Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma",
        "Unresectable Renal Cell Carcinoma",
        "Unresectable Skin Squamous Cell Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Breast Adenocarcinoma",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Neoantigen Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2022-03-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269381"
    },
    {
      "nct_id": "NCT03288545",
      "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Urinary Bladder Neoplasms",
        "Urologic Neoplasms",
        "Renal Pelvis Neoplasms",
        "Urothelial Cancer",
        "Ureteral Neoplasms",
        "Urethral Neoplasms"
      ],
      "interventions": [
        {
          "name": "enfortumab vedotin (EV)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 348,
      "start_date": "2017-10-11",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 83,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288545"
    },
    {
      "nct_id": "NCT00005831",
      "title": "Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Bladder Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Squamous Cell Carcinoma of the Bladder",
        "Stage IV Bladder Cancer",
        "Transitional Cell Carcinoma of the Bladder"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2000-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-14",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005831"
    },
    {
      "nct_id": "NCT03284385",
      "title": "Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Locally Advanced Clear Cell Renal Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-01-29",
      "completion_date": "2027-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 29,
      "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03284385"
    },
    {
      "nct_id": "NCT03592472",
      "title": "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Abexinostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Xynomic Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2018-07-17",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03592472"
    },
    {
      "nct_id": "NCT00003105",
      "title": "Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1997-09",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2013-07-03",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003105"
    },
    {
      "nct_id": "NCT03513952",
      "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Bladder Urothelial Carcinoma",
        "Advanced Ureter Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Bladder Urothelial Carcinoma",
        "Recurrent Renal Pelvis Urothelial Carcinoma",
        "Recurrent Ureter Urothelial Carcinoma",
        "Recurrent Urethral Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Stage III Renal Pelvis Cancer AJCC v8",
        "Stage III Ureter Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Unresectable Bladder Urothelial Carcinoma",
        "Unresectable Renal Pelvis Urothelial Carcinoma",
        "Unresectable Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Glycosylated Recombinant Human Interleukin-7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography and Computed Tomography Scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2019-06-05",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-26",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 9,
      "location_summary": "Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513952"
    },
    {
      "nct_id": "NCT03602079",
      "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2 Gene Mutation",
        "HER-2 Gene Amplification",
        "HER2 Positive Gastric Cancer",
        "Salivary Gland Cancer",
        "Salivary Gland Tumor",
        "Salivary Gland Carcinoma",
        "Salivary Gland Neoplasms",
        "Lung Cancer",
        "Colo-rectal Cancer",
        "Rare Diseases",
        "Solid Tumor",
        "Recurrent Gastric Cancer",
        "Recurrent Colon Cancer",
        "Recurrent Breast Cancer",
        "Head and Neck Cancer",
        "Head and Neck Carcinoma",
        "Bladder Cancer",
        "Cervical Cancer",
        "Liver Cancer",
        "Bile Duct Cancer",
        "Urologic Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Rectal Cancer",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Renal Cell Cancer",
        "Rectal Cancer Stage II",
        "Rectal Cancer Stage I",
        "Rectal Cancer Stage III",
        "Skin Cancer",
        "Mouth Cancer",
        "Lip Cancer Stage I",
        "Tongue Cancer",
        "Breast Neoplasm Malignant Primary",
        "Larynx Cancer",
        "Tonsil Cancer",
        "Palate Cancer",
        "Mucoepidermoid Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Mucinous Adenocarcinoma Gastric",
        "Mucinous Breast Cancer Recurrent",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "A166",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Klus Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-07-16",
      "completion_date": "2022-01-12",
      "has_results": false,
      "last_update_posted_date": "2023-08-03",
      "last_synced_at": "2026-05-22T07:51:18.470Z",
      "location_count": 10,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602079"
    }
  ]
}